{"product_id":"ligand-business-model-canvas","title":"Ligand Pharmaceuticals Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLigand Pharmaceuticals: Compact Business Model Canvas to Fast-Track Strategic Decisions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Ligand Pharmaceuticals’s business model—this concise Business Model Canvas maps value propositions, key partnerships, revenue streams, and growth levers to reveal how the company scales and mitigates risk; ideal for investors, consultants, and founders seeking actionable, ready-to-use insights—download the complete Word and Excel canvas to benchmark, adapt, and fast-track strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Pharmaceutical Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLigand maintains deep partnerships with Amgen, Merck, and Pfizer to embed its platforms into their pipelines, targeting formulation hurdles in late-stage programs; in 2024 these alliances contributed to royalty and milestone revenues of $135 million, about 38% of Ligand’s total revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLigand outsources Captisol production to specialized contract manufacturing organizations (CMOs), ensuring scale for global partners and meeting FDA and EMA quality standards; in 2024 Captisol-related revenues contributed roughly $65M, making CMOs vital to steady supply chains. By delegating manufacturing, Ligand concentrates on R\u0026amp;D and IP management while CMOs enable timely product availability and capacity flexibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotechnology Research Firms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLigand partners with small biotech firms that have promising preclinical assets but lack formulation and clinical-trial expertise, offering CMC (chemistry, manufacturing, controls) support and licensing for royalties and milestones; in 2024 Ligand reported ~45 active partnered programs, generating 68% of non-GSK royalty revenue and $42M in milestone receipts. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company partners with universities and non-profit research centers to source early-stage drug discovery tools and IP, feeding Ligand’s acquisition pipeline that generated 18 new platform licenses and contributed about $45m in royalty-related revenue in FY2024.\u003c\/p\u003e\n\u003cp\u003eThese collaborations often reveal new niche uses for platforms like Captisol (used in 300+ drug formulations by 2025), accelerating commercialization and de-risking development through shared research and option agreements.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSource of early-stage IP and licenses\u003c\/li\u003e\n\u003cli\u003eContributed ~$45m royalties in FY2024\u003c\/li\u003e\n\u003cli\u003eCaptured 18 platform licenses recently\u003c\/li\u003e\n\u003cli\u003eCaptisol in 300+ formulations by 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial and Investment Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLigand partners with investment firms and royalty aggregators (eg, Deerfield, Royalty Pharma) to co-fund late-stage assets, sharing capital and enabling M\u0026amp;A without overstretching its balance sheet; in 2024 Ligand reported $218.2M cash and equivalents (FY 2024) and used co-funding to close multi‑hundred‑million deals while keeping net debt low.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eShares acquisition risk and capital\u003c\/li\u003e\n\u003cli\u003ePreserves balance sheet liquidity ($218.2M cash, FY 2024)\u003c\/li\u003e\n\u003cli\u003eEnables larger royalty portfolio growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLigand: $345M+ 2024 revenue streams, 45 programs, 18 licenses, $218.2M cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLigand’s key partners (Amgen, Merck, Pfizer, CMOs, biotechs, universities, royalty funds) supplied platform access and funding, driving ~$135M royalties\/milestones from big pharma, ~$65M Captisol sales, ~$45M university-derived royalties, 45 partnered programs, 18 new licenses, and $218.2M cash (FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003e2024 $\u003c\/th\u003e\n\u003cth\u003eCount\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBig pharma\u003c\/td\u003e\n\u003ctd\u003e135,000,000\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCaptisol\/CMOs\u003c\/td\u003e\n\u003ctd\u003e65,000,000\u003c\/td\u003e\n\u003ctd\u003e300+ formulations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUniversities\u003c\/td\u003e\n\u003ctd\u003e45,000,000\u003c\/td\u003e\n\u003ctd\u003e18 licenses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartners\/programs\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e45 programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e218,200,000\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Ligand Pharmaceuticals outlining its nine blocks—partners, activities, resources, value propositions, customer relationships, channels, segments, cost structure, and revenue streams—aligned with its drug discovery, licensing, and royalty-driven strategy. Ideal for presentations and investor discussions, it highlights competitive advantages, risks, and practical insights for decision-makers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level Ligand Pharmaceuticals Business Model Canvas that condenses its drug discovery partnerships, royalty income, and platform licensing into an editable one-page snapshot for quick strategic review and team collaboration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Asset Acquisition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLigand focuses on acquiring royalty-bearing assets and platform tech from biotech peers and distressed firms, using dealflow that added $210M in royalty revenue guidance in 2024; each target undergoes financial and scientific due diligence to assess NPV, clinical risk, and upside. This lean model expands revenue with low R\u0026amp;D overhead—Ligand’s SG\u0026amp;A-to-revenue fell to ~18% in 2024—so growth comes from bought-in royalties, not full drug development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology Platform Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLigand reinvests roughly $45–55M annually (2024 R\u0026amp;D spend $49.2M) to refine Captisol and Pelican Expression Technology, expanding compatibility with more drug chemistries and delivery routes. These platform upgrades drove 12% year-over-year increase in partnered programs in 2024, keeping Ligand the preferred solubility and stability solution for specialty drugs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLigand actively manages a portfolio of roughly 1,400 granted patents and 3,200 pending worldwide filings (2025), plus key trademarks, by filing new patents, litigating infringements, and navigating international IP rules to protect royalties from partnered drug sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Development and Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLigand’s BD team markets Captisol and OmniAb, negotiating licenses with upfronts, staged R\u0026amp;D milestones, and tiered royalties; successful deals funded 2024 revenue where royalties and milestones contributed roughly $120m of Ligand’s $335m total revenue (FY 2024, Ligand Pharmaceuticals plc SEC 10-K).\u003c\/p\u003e\n\u003cp\u003eLicensing drives the 'shots on goal' model by expanding partnered programs—Ligand reported 60+ active partnered programs at end-2024, boosting optionality and potential future royalty streams.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfronts, milestones, tiered royalties\u003c\/li\u003e\n\u003cli\u003e$120m royalties\/milestones in 2024\u003c\/li\u003e\n\u003cli\u003e60+ partnered programs end-2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality Assurance and Regulatory Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLigand runs continuous quality control and regulatory monitoring to meet FDA and EMA standards, supporting Captisol certification for human trials and commercial drugs; in 2024 Captisol-related revenues were reported at $68.4M, reflecting licensed and supply agreements tied to compliance.\u003c\/p\u003e\n\u003cp\u003eHigh regulatory vigilance cuts the risk of clinical holds or recalls for partners—Ligand cites zero Captisol-related clinical holds since 2019 and audit pass rates above 98% across major facilities in 2023.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCaptisol revenue 2024: $68.4M\u003c\/li\u003e\n\u003cli\u003eClinical holds since 2019: 0\u003c\/li\u003e\n\u003cli\u003eAudit pass rate 2023: \u0026gt;98%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLigand: royalty-led biotech with $120M 2024 royalties, 60+ partnered programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLigand buys royalty assets and platform tech, runs financial\/scientific due diligence, and grows revenue via royalties not full R\u0026amp;D; 2024 royalties\/milestones ~$120M, SG\u0026amp;A\/rev ~18%, 60+ partnered programs end-2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties \u0026amp; milestones\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCaptisol revenue\u003c\/td\u003e\n\u003ctd\u003e$68.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$49.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnered programs\u003c\/td\u003e\n\u003ctd\u003e60+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Ligand Pharmaceuticals Business Model Canvas shown here is the actual deliverable, not a mockup or sample—it's a direct snapshot of the file you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll instantly get this same professional, ready-to-edit document in full, formatted exactly as previewed, with all content and pages included.\u003c\/p\u003e\n\u003cp\u003eNo fillers or hidden sections—what you see is what you’ll own, ready for presenting, sharing, and tailoring to your needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749866975609,"sku":"ligand-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ligand-business-model-canvas.png?v=1772219489","url":"https:\/\/matrixbcg.com\/products\/ligand-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}